Exploring IP in a Space Sector Product

​
May 9, 2025

Introduction

Innovative space sector businesses generate IP all the time. But it can be difficult to appreciate the range of IP being generated, or the value of that IP.

In order to help illustrate, we've come up with a space sector product of our own*. We'll use this product as the basis of a worked example, to show the range of IP that could potentially be protected, and the value that this could provide.

*This is not a real product. The idea was inspired by this NASA document on State-of-the-Art of Small Spacecraft Technology, published 12 February 2024. The imaginary product is for the purposes of illustrating example IP issues only, and it is not intended to relate to any existing (or future) actual product.

Technological background to the product

The linked NASA document explains that the two main modes of communication between ground terminals and satellites are FSO (Free Space Optics) and RF (radio frequency). This is because the atmosphere and the ionosphere together are opaque in other parts of the electromagnetic spectrum.

As the document states, there are advantages and disadvantages to each of FSO and RF. However, wouldn't it be useful to have a communications terminal with the advantages of both?

The product

The (imaginary) product is a communications terminal that combines both FSO and RF transceivers, and which has a controller that controls whether FSO, RF or both are used in communications, so that at any given time, the most appropriate mode is used.

The control is based on multiple input measurements representing the current environmental and/or operational conditions. Example measurements include:

  • the data rate needs (FSO allows a higher data rate so may be preferable when high data rate applications are in use, or both FSO and RF may be used together to maximise data rate);
  • the weather conditions in the communications path (FSO is more affected by cloud cover so in this case it may be better to use RF).

These measurements are input to a control algorithm, implemented in software, which outputs a determination of whether RF or FSO or both should be used for the current conditions. For example, the algorithm might involve a look-up in a database storing empirically derived mappings of conditions onto communication modes. A controller controls the terminal to use RF and/or FSO based on the output of the algorithm.

The control may be performed by either the ground station terminal or the satellite terminal. The control result determined by one terminal may be communicated to and used by the other terminal. It is also conceivable that the control may be performed by another entity (such as a datacentre at which the algorithm is executed) in communication with the ground station and/or the satellite terminal.

Exploring IP

Possible IP in the product

Possible IP in the product might include (among others):

  • patentable inventions in the control technique and the terminals;
  • copyright in the code for executing the control;
  • possible database rights in the database.

Protecting the IP

The product and/or control technique could in principle be protected using Trade Secrets or Patents.

A trade secret is confidential know-how or other information that is valuable to a business because it is secret, and for which reasonable steps have been taken to keep the information secret. If someone obtains a trade secret without the owner's permission, then remedies can be sought in court, such as an injunction and damages.

A patent is a time-limited (up to 20 years) right to prevent others from using the owner's (new and non-obvious) invention in a given territory. A patent would be obtained by filing and prosecuting to grant a patent application for the invention. Not all software is patentable. However, we believe the present control technique would be considered patentable (e.g. at the European Patent office and the UK IPO) as it controls a technical process.

In contrast, it may not be possible to rely on trade secrets to protect the control technique. For example, if the control is performed at a ground station, which may be sold unconditionally or otherwise available to the public, then trade secret protection may not be available as it may not be possible to keep the control process a secret.

Further, patent protection could offer stronger protection for the control technique than trade secret protection, as it would provide protection even where information about the process is later publicly leaked or disclosed, and even where someone else later comes up with the same idea independently. (For a more detailed comparison of Trade Secrets vs. Patents in the UK space sector, please see our related article here).

It would therefore be worthwhile to consider applying for patent protection for the control technique invention (assuming of course that the control technique had not yet been publicly disclosed).

The copyright in the code for executing the control process exists automatically (provided the code is original). Copyright allows the owner to prevent others from copying or distributing the code (or adaptations of the code) without permission.

Similarly, a database right in the database may exist automatically (provided there has been sufficient investment in obtaining, verifying or presenting the data). Unlike copyright, the data does not have to be original. The database right allows the owner to prevent others from extracting data from, or otherwise reutilizing, a qualifying database.

The value in the IP

Patenting the control process would provide a right to prevent others from performing the same invention (even if they later come up with the same idea independently), which would give a significant competitive edge.

Alternatively, the patent rights could be sold or licensed to others, which may generate significant revenue streams. Further, the patent (or patent application) would be valuable tool for attracting investment and for marketing the innovation.

The copyright in the code could be licensed to others to use. This could provide an additional source of revenue. Alternatively, the code could be released under an open source software license, which might promote others to adopt the control protocol, which may in turn improve uptake (and hence sales) of the product.

Similarly, the database right can be licensed for others to use the database. This may offer a means by which the investment in obtaining the empirical data can be monetized.

What and where to patent

A patent application for this product might include claims covering the control method, the terminal, the system of the ground station and satellite terminals (as well as other control entities); and a computer program that performs the control method. This would allow patent protection to be pursued for a wide range of aspects of the product.

Regarding where (i.e. in which jurisdictions) to apply for patent protection, the method may be performed by a ground station, a satellite, or possibly another entity (such as a datacentre executing the control algorithm). For space objects such as a satellite in space, the relevant jurisdiction is the state where the space object is registered for launch (for more detail on this, see the ‘patent' section of our related article here). Accordingly, it would be prudent to consider applying for patent protection in the main jurisdictions where the ground station will be manufactured, sold, or used; where the satellite will be manufactured or registered for launch; and/or where the control algorithm is likely to be executed.

It is noted that the new European patent with unitary effect (the so called unitary patent) can provide uniform patent protection in multiple EU member states (currently 18 at the time of writing). Accordingly, an example patent strategy for this product might be to file a patent application in Europe (at the European Patent Office) and the US (at the US Patent and Trademark Office). If granted, these would together provide wide coverage across Europe and the US.

Other IP considerations

It might be that the control algorithm is implemented using (someone else's) open source code. In that case, it would be important to make sure that the obligations of the open source licence(s) under which the code is provided are identified, understood, and complied with. If this is not done, then this opens the risk of copyright (and possibly also patent) infringement.

Further, it may be that aspects of the product or control process are covered by someone else's existing patents. It is generally advisable to perform a Freedom to Operate search for patents covering the product in relevant jurisdictions, in order to be better informed of the potential infringement risks that may exist. Further, it is generally better to know about infringement risks and manage them in advance, if possible, in order to avoid surprise "cease and desist" letters after the product operation and marketing is already in full swing.

Conclusion

As we've seen in this worked example, a space sector product can involve various forms of IP. Protecting this IP can provide not only a competitive advantage, but value in other forms, such as opening up additional revenue streams, attracting investment, and promoting uptake. An effective IP strategy will look to maximise the value in the IP, to help provide the best possible outcomes for the business. If you would like to discuss protecting IP in your product, or ways of optimising your IP strategy, do feel free to get in contact.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​